№ files_lp_3_process_9_32324
File format: docx
Character count: 1763
File size: 30 KB
Clinical study of Yaq-001 as a novel therapy for cirrhosis patients, evaluating its effects in both animal models and a multicenter clinical trial.
Year:
2024
Note:
Region / City
Topic:
Clinical Trials, Gastroenterology, Cirrhosis
Document Type:
Scientific Article
Author:
Liu J, MacNaughtan J, Kerbert A, et al.
Target Audience:
Medical Researchers, Healthcare Professionals
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
Not specified
Region / City:
Not specified
Subject:
Medical Pathophysiology, Heart Failure, Arrhythmias
Document Type:
Textbook, Medical Reference
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Healthcare professionals, Medical students
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2024
Region / city:
International
Theme:
Psychiatry, Bariatric Surgery
Document type:
Review Article
Author:
Various
Target audience:
Healthcare professionals, psychiatrists, bariatric surgeons
Period of validity:
Ongoing
Approval date:
2024
Date of modifications:
Not specified
Year:
2021
Region / City:
Tangier, Morocco
Topic:
Hepatic Cirrhosis, Patient Knowledge, Therapeutic Education
Document Type:
Research Study
Author(s):
R. ARDIF, W. BOUKAMZA, I. ELFADLI, A. AKJAY, H. OUAYA, H. MEYIZ, I. MELLOUKI
Target Audience:
Medical professionals, researchers, healthcare providers
Study Period:
2020-2021
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2024
Region / City:
Nanfang Hospital
Theme:
Hepatology, Cancer Diagnosis
Document Type:
Scientific Methodology
Institution:
Nanfang Hospital
Author:
Unspecified
Target Audience:
Medical Professionals, Researchers
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Context:
This document presents the diagnostic criteria for cirrhosis and hepatocellular carcinoma, including imaging techniques and laboratory results, based on a multi-center study with radiomics and deep learning features for prediction models.
Authors:
Petar Avramovski; Julijana Petrovska; Maja Avramovska
Affiliations:
St. Clement of Ohrid University – Bitola; Clinical Hospital – Bitola
Country:
North Macedonia
City:
Bitola
Medical Field:
Gastroenterology; Hepatology; Diagnostic Ultrasound
Type of Document:
Scientific research abstract
Study Design:
Observational clinical study
Study Population:
325 patients with non-alcoholic fatty liver disease (NAFLD)
Average Age of Participants:
54.2±8.5 years
Institutions Involved:
Department of Ultrasonography; Department of Gastroenterohepatology; Department of Gynecology and Obstetrics, Clinical Hospital – Bitola
Methods:
B-mode ultrasound imaging, echogenicity analysis software, laboratory tests for platelets, ALT and AST, calculation of FIB-4 score
Diagnostic Indicators Studied:
Hepatorenal Index (HRI); Fibrosis-4 (FIB-4) score
Conditions Examined:
Non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; liver fibrosis; cirrhosis
Patient Group Classification:
Mild NAFLD; moderate NAFLD; severe NAFLD; significant fibrosis (≥F2); advanced fibrosis (≥F3); cirrhosis (F4)
Keywords:
hepatorenal index; FIB-4 score; NAFLD; liver fibrosis; cirrhosis; ultrasound diagnostics
Year:
2013–2021
Region / City:
United States, Canada
Subject:
Cirrhosis and liver disease coding
Document type:
Supplementary table / Research data
Institution:
University of Pennsylvania health system; Parkland Hospital; Outpatient hepatology clinic in Toronto
Authors:
Nehra, Goldberg, Niu, Philip, Hagstrom
Target population:
Patients with cirrhosis or liver disease
Validation status:
Mixed validated and non-validated algorithms
Coding system:
ICD-9-CM, ICD-10-CM
Conditions covered:
Cirrhosis, decompensated cirrhosis, hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma, liver transplant
Data extraction method:
Algorithm-based diagnosis code identification
Clinical relevance:
Identification and classification of liver disease conditions for research and clinical coding purposes
Reference:
Peer-reviewed studies and expert consensus statements
Supplementary notes:
ICD-10-CM codes derived using GEM mapping when not directly validated
Year:
Not specified
Region / City:
Not specified
Topic:
Medical Research / Hepatology
Document Type:
Research Table
Author:
Not specified
Target Audience:
Medical professionals, researchers
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Not specified
Topic:
Microbiome diversity in liver disease
Document Type:
Scientific figure description
Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers and clinicians in hepatology and microbiology
Study Population:
Patients with infected decompensated cirrhosis
Analysis Methods:
Phylogenetic diversity (PD) whole tree, principal component analysis
Outcome:
Comparison of survival and mortality during admission and follow-up
Year:
Not specified
Medical condition:
Cirrhosis
Study focus:
2-year all-cause mortality
Methodology:
Multivariate Cox proportional hazards analysis
Clinical variables analyzed:
Hepatic encephalopathy (HE); neutrophil-to-lymphocyte ratio (NLR); ascites; alcohol use; MELD 3.0 score >18
Population:
Hospitalized patients with cirrhosis
Outcome measure:
Hazard ratio (HR) with 95% confidence interval (CI) and p value
Clinical scoring system:
MELD 3.0 (Model for End-Stage Liver Disease)
Document type:
Supplementary statistical table
Statistical indicators:
Hazard ratio (HR); confidence interval (CI); p value
Year:
1993-2022
Region / Country:
Multicenter / International
Topic:
Infectious complications in cirrhosis
Document Type:
Supplementary table
Source / Journal:
Various peer-reviewed medical journals
Authors:
Multiple, see references
Study Type:
Observational studies
Sample Size:
Variable across studies
Assessment Criteria:
Sample frame, sampling method, data coverage, identification methods, measurement reliability, statistical analysis, response rate, risk of bias
Target Population:
Patients with liver cirrhosis
Key Outcomes:
Infection prevalence, risk factors, mortality, multidrug resistance
Endorsement / Approval:
Peer-reviewed publication
Data Collection Period:
1993–2022
Language:
English
Quality Assessment:
Low to moderate risk of bias
Year:
2023
Journal:
World Journal of Gastroenterology
Manuscript Number:
82876
Type:
Mini Review
Authors:
Giuseppe Marrone, Amato Serra, Luca Miele, Marco Biolato, Antonio Liguori, Antonio Grieco, Antonio Gasbarrini
Affiliation:
Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Corresponding Author:
Giuseppe Marrone, MD, PhD
Received Date:
December 28, 2022
Revised Date:
January 24, 2023
Accepted Date:
April 20, 2023
Published Online:
May 21, 2023
Keywords:
Branched-chain amino acids, Hepatic encephalopathy, Sarcopenia, Liver cirrhosis
Focus:
Review of clinical evidence for BCAAs supplementation in cirrhosis-related complications
Patient Population:
Individuals with liver cirrhosis
Complications Discussed:
Hepatic encephalopathy, Sarcopenia
Treatment Approaches:
BCAAs supplementation, non-absorbable disaccharides, antibiotics, supportive therapies
Evidence Type:
Literature review of clinical studies and guidelines